Target intelligence / Profile preview

Grass pollen allergoid

Molecular classification
Other
01

Overview

Grass pollen allergoids are chemically modified allergen extracts derived from grass species such as Phleum pratense (Timothy grass) and Dactylis glomerata (Orchard grass), primarily utilized in allergen-specific immunotherapy (AIT). The modification process, typically involving polymerization with agents like glutaraldehyde or formaldehyde, alters the molecular structure of the allergens to reduce their IgE-binding capacity while maintaining their immunogenicity. This allows for the administration of higher allergen doses with a reduced risk of immediate systemic allergic reactions compared to native extracts. Biologically, the source allergens often include proteins from the beta-expansin family (Group 1 allergens) and ribonuclease-like proteins (Group 5 allergens), which naturally play roles in plant cell wall extension and pollen germination. In clinical practice, grass pollen allergoids are used to treat allergic rhinitis and allergic asthma by restoring immune tolerance. These agents target the immune system by modulating the T-cell response, inducing regulatory T cells, and promoting a shift from pro-inflammatory Th2 responses to tolerogenic profiles. This shift results in the production of allergen-specific blocking antibodies, particularly IgG4, which inhibit the IgE-mediated activation of mast cells and basophils. While effective for long-term disease modification, safety challenges include the potential for anaphylaxis and interactions with drugs such as beta-blockers or MAOIs, which can impede the effectiveness of emergency epinephrine treatment.

Other names
Modified grass pollen extractGlutaraldehyde-modified grass pollen allergensFormaldehyde-treated grass pollen extractGrass pollen allergen extract, modifiedAllergoids
02

Mechanism of action

Induces peripheral T-cell tolerance by promoting regulatory T-cell (Treg) activity, shifting the immune response from a Th2 to a Th1/Treg profile, and stimulating the production of allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding.

03

Biological functions

Immune responseOther
04

Disease associations

InflammationOther
05

Safety considerations

AnaphylaxisSystemic allergic reactionsUrticariaAngioedemaAsthma exacerbationLocal injection site reactions
06

Interacting drugs

Epinephrine

9 more in the full profile.

07

Biomarkers

Allergen-specific IgE (sIgE)Allergen-specific IgG4 (sIgG4)Skin prick test (SPT) wheal diameterInterleukin-4 (IL-4)Interleukin-10 (IL-10)Eosinophil cationic protein (ECP)

Beyond the preview

Go deeper on Grass pollen allergoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grass pollen allergoid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call